Self-Reported Long COVID and Its Impact on COVID-19-Related Worries and Behaviors After Lifting the COVID-19 Restrictions in China.

Publication date: Jan 29, 2025

Since the lifting of the COVID-19 restrictions in China in November 2022, there has been a notable surge in the COVID-19 infection rate. Little is known about the prevalence of long COVID among the general adult population and its impact on COVID-19-related worries and behaviors after the policy change. This cross-sectional study recruited 1530 adults with prior COVID-19 infection in Guangzhou from February to March 2023. Logistic regression analyses and trend analyses were performed to investigate the associations between long COVID- and COVID-19-related worries and preventive behaviors. The estimated prevalence of long COVID among adults in China was 18. 0% (95% confidence interval: 16. 1% to 20. 0%). Common long COVID symptoms included cough (60. 7%), fatigue (47. 6%), dyspnea (34. 5%), palpitation (26. 2%), and insomnia (25. 1%). Adjusted for background variables, individuals with long COVID exhibited higher level of COVID-19-related worries compared to those who had fully recovered from the infection (reference: without long COVID; adjusted odds ratios ranged from 1. 87 to 2. 55, all p values < 0. 001). Participants primarily expressed worries regarding the potential for COVID-19 reinfection, the impact of the pandemic on daily life, the increasing number of COVID-19 cases and deaths, and the capacity of the healthcare system. While long COVID did not statistically significantly affect their preventive behaviors. Long COVID was prevalent among the general adult population in China after lifting the COVID-19 restrictions, and it had a significant impact on COVID-19-related worries. This study highlights the importance of monitoring the mental health of individuals with long COVID and developing targeted intervention strategies to improve their adherence to preventive measures.

Open Access PDF

Concepts Keywords
China COVID-19-related worries
February long COVID
Healthcare mental health
Pandemic preventive measures

Semantics

Type Source Name
disease MESH Long COVID
disease MESH COVID-19
disease MESH infection
disease MESH dyspnea
disease MESH insomnia
disease MESH COVID-19 reinfection
disease IDO intervention
disease MESH reinfection
disease MESH death
disease MESH sequelae
disease MESH sleep disorders
disease MESH joint pain
disease MESH eating disorders
disease IDO history
disease IDO host
disease IDO immunosuppression
drug DRUGBANK Trestolone
disease MESH depression
disease MESH anxiety
disease MESH chest pain
disease MESH tinnitus
disease MESH cognitive impairment
disease MESH education level
disease MESH marital status
disease MESH chronic diseases
disease IDO nucleic acid
disease IDO symptom
drug DRUGBANK Etoperidone
disease IDO production
drug DRUGBANK Aripiprazole
disease MESH brain fog
disease MESH symptom burden
disease MESH myocardial infarction
disease MESH psychological stress
disease IDO acute infection
disease MESH psychological well being
disease IDO susceptibility
disease MESH phobias
drug DRUGBANK Coenzyme M
disease MESH privacy
disease MESH Respiratory Infections
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Carboxyamidotriazole
disease MESH loneliness
disease MESH PTSD
disease MESH comorbidity
drug DRUGBANK Sulfasalazine
disease MESH syndrome
disease MESH Allergy
disease MESH Virus Disease

Original Article

(Visited 1 times, 1 visits today)